CROSS-BORDERS VENTURE CAPITAL INVESTMENTS

Wednesday, September 28th (14h30-16h00)
Room A

Sponsored by

Information:

To make a venture capital investment in the international markets can result in higher costs due to increased transaction costs and the difficulty in obtaining reliable information about the object of investment. However, the potential benefits are numerous: geographical risk diversification and a potential return on investment higher than the local market offers. For the investor and the market in which the investment is done, the entry of international capital compensates for the potential limited supply of local venture risk capital.

In 2015 a Spanish company, Laboratorios Sanifit, starred in one of the largest venture capital investments made in Europe that year. Worth 41 million dollars, the investment led by several national and international funds: Ysios Capital Partners, Lundbeckfond Ventures, Forbion Capital Partners, Gilde Healthcare, Caixa Capital Risc, Edmon de Rothschild Investment Partnets and Baxter Ventures.

In this session, in addition to using this example as a case study, we will discuss the risks, benefits and challenges of cross-border cooperation from the point of view of the investor and also from that of the company receiving the investment.

Moderator:

• Joël Jean-Mairet: Managing Partner, YSIOS CAPITAL PARTNERS  (Spain)

Speakers:

• Naveed Siddiqi: Partner, EDMOND DE ROTHSCHILD INVESTMENT PARTNERS (France)
  
• Casper Breum: Senior Partner, LUNDBECKFONDEN VENTURES (Denmark)
• Edwin de Graaf: Managing Director, GILDE HEALTHCARE PARTNERS (Netherlands)
• Joan Perelló: Founder & CEO, LABORATORIOS SANIFIT (Spain)
• Carlos Esteban: Investment Director, CAIXA CAPITAL RISC (Spain)